NCT02702492

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Karyopharm Therapeutics Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).

Detailed description

This is a first-in-human, multi-center, open-label clinical study with separate Dose Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies (including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard therapeutic options considered useful by the investigator have been exhausted.

Conditions

• Solid Tumors
• NHL

Interventions

Type	Name	Description
DRUG	KPT-9274
DRUG	Niacin ER
DRUG	Nivolumab

Timeline

• Start date: 2016-06-08
• Primary completion: 2021-01-26
• Completion: 2021-01-26
• First posted: 2016-03-08
• Last updated: 2024-11-25
• Results posted: 2024-11-25

Locations

8 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study